Healthcare Pharmaceuticals Ltd, one of the largest pharmaceutical companies in Bangladesh and Eli Lilly and Company, a global healthcare company recently announced the launch of the Trulicity drug for Type-2 diabetes in Bangladesh.
Trulicity is the first once-weekly, injectable medication designed to improve blood sugar control in adults with Type-2 diabetes, according to a press release.
Trulicity offers patient benefits beyond glycemic control and the convenience associated with a once-weekly dose. Studies done on Trulicity have established its cardiovascular safety and weight reduction potential, the press release read.
"The launch of Trulicity in Bangladesh will open newer avenues in diabetes management and provide healthcare professionals with a better way to manage diabetes," said Mr Halimuzzaman, DMD & CEO, Healthcare Pharmaceuticals Ltd.
"Diabetes is a big burden on the healthcare system in Bangladesh. More than eight million people live with diabetes in the country and their treatment needs vary," said Luca Visini, Managing Director for South Asia, Eli Lilly and Company.
"This launch is an important milestone in our journey to help more and more patients, and their caregivers, with the treatment support they need," Luca Visini added.
"Many Type-2 diabetes patients do not meet their treatment goals in Bangladesh. Trulicity has been designed keeping patients' needs and convenience in mind," said Professor A K Azad Khan, President, Diabetic Association of Bangladesh (BADAS).
Trulicity is a prescription drug that should be taken only on the advice of registered physicians who deal with diabetic patients, the press release added.